Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France. Show more

Location: 50 rue de Dijon, Daix, 21121, France | Website: https://inventivapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

606.8M

52 Wk Range

$2.11 - $7.98

Previous Close

$4.16

Open

$4.04

Volume

92,316

Day Range

$3.90 - $4.19

Enterprise Value

743.4M

Cash

122.5M

Avg Qtr Burn

-22.83M

Insider Ownership

0.00%

Institutional Own.

5.18%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.